Cozaar News
Carmel biotech firm inks Merck deal - Indianapolis Star
Merck's top products include Singulair for asthma, Cozaar and Hyzaar for hypertension, Fosamax for osteoporosis and Zocor for cholesterol, according to ...
Merck Pays More Than $400 Million to Settle Federal, State ... - PharmaLive.com (press release)
Merck employed four schemes to grab or maintain market share for drugs including Vioxx(R), Zocor(R), Cozaar(R), Fosamax(R), Maxalt(R), and Singulair(R), ...
Carmel biotech firm inks Merck deal - Indianapolis Star
Merck's top products include Singulair for asthma, Cozaar and Hyzaar for hypertension, Fosamax for osteoporosis and Zocor for cholesterol, according to ...
Merck Posts $1.6 Billion Q4 Loss - Los Angeles Times
Sales jumped 20 percent for Singulair, to $1.15 billion, and rose 3 percent, to $891 million, for related blood pressure drugs Cozaar and Hyzaar. ...
Merck To Pay Huge Sum - Evening Bulletin
Merck allegedly employed schemes to maintain market share for the drugs Vioxx, Zocor, Cozaar, Fosamax, Maxalt and Cingulair. In Philadelphia, US prosecutors ...
Merck's Patent On Blockbuster Osteoporosis Drug Fosamax Runs Out - Trading Markets (press release)
... Fosamax has run out and faces its next big patent expiration in 2010, when the $3 billion-a-year Cozaar/Hyzaar hypertension franchise loses protection. ...
Merck Pays More Than $400 Million to Settle Federal, State ... - PR Newswire (press release)
Merck employed four schemes to grab or maintain market share for drugs including Vioxx(R), Zocor(R), Cozaar(R), Fosamax(R), Maxalt(R), and Singulair(R), ...
Search By Symbol - RTT News
Merck's antihypertensive medicines, Cozaar and Hyzaar, recorded global sales of $891 million in the quarter, representing an increase of 3% from the ...
Merck & Co., Inc. Q4 2007 Earnings Call Transcript - Seeking Alpha
Our most established products also continue to deliver strong performances, including SINGULAIR, COZAAR, HYZAAR, ZETIA, and VYTORIN. ...
Merck Posts $1.6 Billion Q4 Loss - The Associated Press
Sales jumped 20 percent for Singulair, to $1.15 billion, and rose 3 percent, to $891 million, for related blood pressure drugs Cozaar and Hyzaar. ...
Cozaar RSS Feed